CN110840893A - 含克莱拉尼的药物组合物及其用途 - Google Patents

含克莱拉尼的药物组合物及其用途 Download PDF

Info

Publication number
CN110840893A
CN110840893A CN201910917756.5A CN201910917756A CN110840893A CN 110840893 A CN110840893 A CN 110840893A CN 201910917756 A CN201910917756 A CN 201910917756A CN 110840893 A CN110840893 A CN 110840893A
Authority
CN
China
Prior art keywords
cancer
weeks
effective amount
therapeutically effective
per day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910917756.5A
Other languages
English (en)
Chinese (zh)
Inventor
维奈·K·柴恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Publication of CN110840893A publication Critical patent/CN110840893A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910917756.5A 2018-12-13 2019-09-26 含克莱拉尼的药物组合物及其用途 Pending CN110840893A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862779128P 2018-12-13 2018-12-13
US62/779,128 2018-12-13
US201962861424P 2019-06-14 2019-06-14
US62/861,424 2019-06-14

Publications (1)

Publication Number Publication Date
CN110840893A true CN110840893A (zh) 2020-02-28

Family

ID=69596002

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910917756.5A Pending CN110840893A (zh) 2018-12-13 2019-09-26 含克莱拉尼的药物组合物及其用途

Country Status (5)

Country Link
US (2) US11602533B2 (https=)
EP (1) EP3893874A4 (https=)
JP (1) JP2022510962A (https=)
CN (1) CN110840893A (https=)
WO (1) WO2020123991A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491693A (zh) * 2020-03-19 2021-10-12 江苏恒瑞医药股份有限公司 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途
CN114470216A (zh) * 2020-10-23 2022-05-13 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
CA3186319A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655564A (zh) * 2012-09-21 2014-03-26 安罗格制药有限责任公司 抑制组成型活性磷酸化flt3激酶的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1641780B1 (en) 2003-06-24 2008-11-12 Pfizer Products Incorporated Processes for the preparation of 1- [(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
US20130230511A1 (en) * 2012-02-03 2013-09-05 Board Of Regents, The University Of Texas System Biomarkers for response to tyrosine kinase pathway inhibitors in cancer
EA039595B1 (ru) 2012-10-05 2022-02-15 Кадмон Корпорейшн, Ллк Нуклеиновые кислоты, кодирующие человеческие анти-vegfr-2/kdr-антитела
MX373894B (es) 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
EP3060654B1 (en) 2013-10-21 2023-03-15 Hemoshear, LLC In vitro model for a tumor microenvironment
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
CN110840893A (zh) * 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103655564A (zh) * 2012-09-21 2014-03-26 安罗格制药有限责任公司 抑制组成型活性磷酸化flt3激酶的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M MICHAEL等: "hase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor", 《BRITISH JOURNAL OF CANCER》 *
李超等: "雷莫芦单抗的药理学和临床研究进展", 《DRUGS AND CLINIC》 *
袁杨等: "VEGF/VEGFR信号通路及其相关抑制剂研究进展", 《WORLD LATEST MEDICINE INFORMATION》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491693A (zh) * 2020-03-19 2021-10-12 江苏恒瑞医药股份有限公司 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途
CN113491693B (zh) * 2020-03-19 2023-11-14 江苏恒瑞医药股份有限公司 法米替尼或其可药用盐在制备治疗Ras突变疾病的药物中的用途
CN114470216A (zh) * 2020-10-23 2022-05-13 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CN114470216B (zh) * 2020-10-23 2024-08-06 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法

Also Published As

Publication number Publication date
EP3893874A4 (en) 2022-08-24
WO2020123991A1 (en) 2020-06-18
JP2022510962A (ja) 2022-01-28
US20200188385A1 (en) 2020-06-18
EP3893874A1 (en) 2021-10-20
US11602533B2 (en) 2023-03-14
US20230181565A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US20230181565A1 (en) Crenolanib combination therapy
Bhargava et al. Development of second-generation VEGFR tyrosine kinase inhibitors: current status
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
Patyna et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity
AU2016244262B2 (en) Combination therapy for the treatment of glioblastoma
Aprile et al. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight
TW201206441A (en) New combination therapy in treatment of oncological and fibrotic diseases
KR20240112932A (ko) 암 치료를 위한 cdk2 억제제 및 cdk4 억제제를 포함하는 방법 및 투여 섭생법
EP4252774A1 (en) Combination therapy for treating pik3ca-mutated cancer
AU2018360559A1 (en) Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2 inhibitors, BCL2/BCLxL inhibitors, and BCLxL inhibitors and methods of use
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
Rogosin et al. Beyond bevacizumab: antiangiogenic agents
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
WO2014189937A1 (en) Specific cancer treatment regimens with ganetespib
K Koutras et al. Angiogenesis as a therapeutic target in breast cancer
Voss et al. Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma
Schvartsman et al. An unusual case of central retinal vein occlusion and review of the toxicity profile of regorafenib in GIST patients
CN121311227A (zh) 用于治疗kras依赖性癌症的法尼基转移酶抑制剂
HK40017631A (en) Pharmaceutical compositions containing crenolanib and use thereof
De Jonge et al. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
Sathornsumetee Therapeutic strategies to target multiple kinases in glioblastoma
WO2014089570A1 (en) Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017631

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200228

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40017631

Country of ref document: HK